Mission statement · Company scope
“Our mission is to become the leader in the development of a new generation of DXL™ -modified monoclonal antibodies that have significantly improved therapeutic potency and novel properties over un-modified monoclonal antibodies.”
In use2007 – now1 sighting
First seenDec 2007Added
Last seenDec 2007Latest observation
Date created—Not published by the organization
Record
- Kind
- Mission
- Scope
- Company
- Style
- Market leadership (primary) · Innovation
- Leads with
- Rank
- Best for
- Climate & health
- Formula
- The [rank] [category] for [who]
- Tone
- Plain
- Length
- 32 words · reading grade 23.4
- Review status
- unreviewed · classifier rules-v0
- Quality score
- 0.74
- Record
- st_6921cf24ac1a4917
- Classification confidence
- 0.67
Sources1 sighting
SEC
SEC EDGAR filingsObserved 2007-12-26 · sec_sentence · 20-F · accession 0001278730-07-000032
View filing ↗0 to compareCompare